Rymo Technologies Raises Seed Funding for Robotic Rehab

Rymo Technologies, an innovator in robotic neuro-rehabilitation, has successfully closed a seed funding round exceeding INR 10 crore (approximately $1.2 million USD). The investment was spearheaded by IAN Angel Fund, the evergreen fund of IAN Group, with contributions from additional angel investors. This capital infusion is earmarked for advancing product development, scaling manufacturing operations, and broadening the company's footprint both domestically within India and internationally, targeting markets in the ASEAN region and the Middle East.

The company, co-founded by Chirag Shah (CEO) and Abhishek Rai (CTO), is strategically addressing a critical deficit in neurological rehabilitation services. With a global surge in conditions like stroke and other neurological disorders, access to advanced therapeutic interventions remains a significant challenge. This is largely due to a scarcity of specialized therapists and the prohibitive expense associated with existing robotic rehabilitation systems, leaving many patients in smaller cities and hospitals underserved.

Rymo Technologies has already established a notable presence within the healthcare sector, boasting over 452 device installations and serving 354 clinical clients. Prominent healthcare institutions such as AIIMS, Apollo Hospitals, and Manipal Hospitals are among its clientele. The company's technology has facilitated more than 15,000 therapy hours for over 7,500 patients, with reported outcomes suggesting recovery times can be accelerated by up to 25 percent.

“Our mission is to make world-class rehabilitation accessible to everyone, ensuring no patient is hindered by financial or infrastructural limitations,” stated Chirag Shah, Co-founder & CEO of Rymo Technologies. “This funding will empower us to expand globally, enhance our technological offerings, and provide more patients and healthcare professionals with access to superior robotic rehabilitation solutions.”

The global neuro-rehabilitation devices market is a substantial and expanding arena, currently valued at approximately $2.16 billion and projected to grow at an annual rate of around 14 percent. This growth is fueled by healthcare systems worldwide actively seeking efficient and scalable solutions for the increasing prevalence of neurological conditions. Rymo is positioning itself to capture a significant share of this market by offering its advanced robotic and AI-assisted rehabilitation technology at accessible price points, enabling mid-sized hospitals and physiotherapy clinics to adopt these cutting-edge services.

Beyond its clinical adoption, Rymo has developed a robust technological framework. This includes patented hardware, proprietary AI algorithms trained on extensive patient data, and a modular system design. The core of its platform is a multi-joint robotic rehabilitation system integrated with AI-driven personalization, aimed at delivering measurable improvements in patient recovery. The company has also made strides in regulatory approvals, achieving US FDA classification as a Class II medical device, and has initiated international expansion through a distribution partnership with Fourier Rehab for the ASEAN markets.